A Randomized, Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of the Effects of Armodafinil (200 mg/Day) Treatment on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome.
Phase of Trial: Phase IV
Latest Information Update: 19 May 2010
At a glance
- Drugs Armodafinil (Primary)
- Indications Sleep apnoea syndrome
- Focus Pharmacodynamics
- 19 May 2010 New trial record
- 19 May 2010 Study details were reported at the 106th International Conference of the American Thoracic Society.